Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9580067 | 0.88 | HDAC4 (0.42) | AOC3HDAC4HDAC2HDAC8TP53 | |
| SCHEMBL18316475 | 0.83 | HDAC4 (0.43) | HDAC4HDAC2HDAC8TP53MAPT | |
| SCHEMBL29364274 | 0.83 | HDAC4 (0.43) | HDAC4HDAC2HDAC8TP53MAPT | |
| SCHEMBL180401 | 0.83 | HDAC4 (0.43) | HDAC4HDAC2HDAC8TP53MAPT | |
| SCHEMBL30987496 | 0.83 | HDAC4 (0.43) | HDAC4HDAC2HDAC8TP53MAPT | |
| SCHEMBL27961266 | 0.80 | ERN1 (0.35) | — | |
| SCHEMBL5883541 | 0.80 | ALDH1A1 (0.42) | ACP3KMT2AAOC3HDAC4HDAC2 | |
| SCHEMBL22245030 | 0.80 | HDAC4 (0.37) | HDAC4HDAC2HDAC8TP53MAPT | |
| SCHEMBL2793025 | 0.80 | PARP1 (0.43) | KMT2AHDAC4HDAC2HDAC8ALDH1A1 | |
| SCHEMBL2793022 | 0.80 | PARP1 (0.43) | KMT2AHDAC4HDAC2HDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142343-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142343-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142343-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8709994-B2 | Fragrance compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2014-04-29 | — | — | US | disclosed |
| EP-2077986-B1 | NOVEL FRAGRANCE COMPOUNDS | GIVAUDAN NEDERLAND SERVICES BV (NL) | 2013-12-04 | — | — | EP | disclosed |
| EP-2657218-A1 | Novel Fragrance Compounds | Givaudan Nederland Services B.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| EP-2657218-A1 | Novel Fragrance Compounds | Givaudan Nederland Services B.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| US-20100069287-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069287-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069287-A1 | Novel Fragrance Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2077986-A1 | NOVEL FRAGRANCE COMPOUNDS | Givaudan Nederland Services B.V. (NL) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008053148-A1 | NOVEL FRAGRANCE COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053148-A1 | NOVEL FRAGRANCE COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-05-08 | — | — | WO | disclosed |
| CN-101068783-A | Processes and intermediates for preparing cysteine protease inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-11-07 | — | — | CN | disclosed |
| CN-1809530-A | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1048715-C | 3-(3-methyl-phenyl)-butanal compound used as purfume | DALIAN CHEMICAL PHYSICS INST (CN) | 2000-01-26 | — | — | CN | disclosed |
| CN-1048715-C | 3-(3-methyl-phenyl)-butanal compound used as purfume | DALIAN CHEMICAL PHYSICS INST (CN) | 2000-01-26 | — | — | CN | disclosed |
| CN-1130169-A | 3-(3-methyl-phenyl)-butanal compound used as purfume | DALIAN CHEMICAL PHYSICS INST (CN) | 1996-09-04 | — | — | CN | disclosed |
| CN-1130169-A | 3-(3-methyl-phenyl)-butanal compound used as purfume | DALIAN CHEMICAL PHYSICS INST (CN) | 1996-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069287-A1 | Novel Fragrance Compounds | C1S, C5, FADS1 | ACP3 4045/4885KMT2A 201/4885ACHE 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.